Sub-Areas to GLP-1:
Enteroinsular Axis
(3)
Effectivity of GLP-1 in Therapy
(5)
Recombinant GLP-1 Proteins
(0)
(Journal Article): Glucagon-like peptide-1 7-36: a physiological incretin in man.
Kreymann B, Williams G, Ghatei MA, Bloom SR (Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London.)
IN:
Lancet
1987; 2(8571):1300-1304
Impact Factor(s) of Lancet: 23.407 (2005), 21.713 (2004), 18.316 (2003), 15.397 (2002), 13.251 (2001)
Fulltext: HTML
ABSTRACT: The physiological role of glucagon-like peptide-1 7-36 amide (GLP-1 7-36) in man was investigated. GLP-1 7-36-like immunoreactivity was found in the human bowel; its circulating level rose after oral glucose and after a test breakfast. When it was infused into seven volunteers at a rate to mimic its postprandial plasma concentration in the fasting state, plasma insulin levels rose significantly and glucose and glucagon concentrations fell. During an intravenous glucose load, it greatly enhanced insulin release and significantly reduced peak plasma glucose concentrations, compared with a control saline infusion, even inducing postinfusion reactive hypoglycaemia. By comparison, infusion of glucose-dependent insulinotropic peptide (GIP) to physiological levels was less effective in stimulating insulin release. These observations suggest that GLP-1 7-36 is a physiological incretin and that it is more powerful than GIP. The observation of greatly increased postprandial plasma GLP-1 7-36 levels in patients with postgastrectomy dumping syndrome suggests that it may mediate the hyperinsulinaemia and reactive hypoglycaemia of this disorder.
TYPE OF PUBLICATION: Original article
|
(Journal Article): Glucagon and other proglucagon-derived peptides. Gut peptides: biochemistry and physiology
Holst JJ, 0rskov C
IN:
Raven Press, New York
1994; :305-340
ABSTRACT: n.a.
TYPE OF PUBLICATION: Review
Articles citing this article:
|
(Journal Article): Renal catabolism of human glucagon-like peptides 1 and 2.
Ruiz-Grande C, Pintado J, Alarcon C, Castilla C, Valverde I, Lopez-Novoa JM (Fundacion Jimenez Diaz, Centro Asociado al Consejo Superior de Investigaciones Cientificas, Madrid, Spain.)
IN:
Can J Physiol Pharmacol
1990; 68:1568-1573
Impact Factor(s) of Can J Physiol Pharmacol: 1.603 (2004), 1.357 (2003), 1.341 (2002), 1.261 (2001)
ABSTRACT: The renal catabolism of [125I]glucagon-like peptide 1 (GLP-1) and [125I]glucagon-like peptide 2 (GLP-2) has been studied both in vivo, by the disappearance of these peptides from the plasma of bilaterally nephrectomized (BNX), ureteral-ligated (BUL) or normal rats, and in vitro, analyzing their catabolism by the isolated, perfused rat kidney. Results from in vivo studies demonstrated that half-disappearance time for both peptides was lower in controls than in BUL rats, and this value in BUL rats was not significantly different from that in BNX rats. In addition, metabolic clearance rate of GLP-1 was higher in control rats than in the other two groups of animals. Urinary clearance rate of both peptides was negligible. In isolated kidney experiments, values for organ clearance of both [125I]GLP-1 and [125I]GLP-2 were similar to those of inulin clearance, which represents the glomerular filtration rate. Urinary clearance of trichloroacetic acid precipitable radioactivity represented less than 1% of total clearance. In conclusion, these results demonstrate a significant role for the kidney in the plasma removal of [125I]GLP-1 and [125I]GLP-2 by a mechanism that involves glomerular filtration and tubular catabolism.
TYPE OF PUBLICATION: Original article
Articles citing this article:
|
(Journal Article): Truncated GLP-l (proglucagon 78-107 amide) inhibits gastrie and pancreatie functions in man.
Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Chrisnansen J, Holst JJ (Department of Surgical Gastroenterology D, Glostrup County Hospital, Copenhagen, Denmark.)
IN:
Dig Dis Sei
1993; 38(4):665-673
Fulltext: HTML
ABSTRACT: We studied the effect of intravenous infusion of synthetic truncated GLP-1 (proglucagon 78-107-amide) on fasting and postprandial gastric acid secretion, gastric emptying, and pancreatic secretion of trypsin and lipase in eight normal volunteers using marker dilution and aspiration technique. The infusion resulted in a plasma concentration of 110 +/- 14 pmol/liter (mean +/- SEM). Truncated GLP-1 significantly inhibited postprandial acid secretion by 43 +/- 11% in spite of unchanged plasma gastrin concentration. Gastric emptying rate decreased significantly; 50% emptying time increased from 16 +/- 2 min to 30 +/- 5 min. Postprandial trypsin and lipase outputs were significantly inhibited by 47 +/- 17% and 40 +/- 9% during truncated GLP-1 infusion. Pancreatic enzyme output was linearly correlated to gastric emptying, and truncated GLP-1 did not affect this relationship, suggesting that the effect on pancreatic secretion was secondary to the effect on gastric emptying. Postprandial insulin and glucagon concentrations were similar with and without truncated GLP-1 infusion in spite of significantly lower blood glucose levels (5.2 +/- 0.2 versus 3.7 +/- 0.3), indicating that GLP-1 stimulated insulin secretion and inhibited glucagon secretion. In conclusion, our results suggest that truncated GLP-1 act as a physiological inhibitor of gastric and pancreatic functions in man.
TYPE OF PUBLICATION: Original article
Articles citing this article:
|
|